Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment ...

A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility. The European Medicines Agency’s (EMA’s) ...

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment ...

Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: primary results from the ...

NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data. The National Institute for Health and Care Excellence (NICE ...

SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients. The 2026 Society of Hematologic Oncology ...

T-DXd plus pertuzumab is now approved for adult patients with HER2-positive unresectable or recurrent breast cancer based on results from the phase 3 DESTINY-Breast09 trial (NCT04784715). Dato-DXd ...

Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.

ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases. Published in Practical Radiation ...

Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial. The FDA has granted fast track designation to cesalatamig (AI-081), an ...

Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC. A supplemental new drug application (sNDA) for ...